Compare Boston Beer Company Inc (SAM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Boston Beer Company Inc trades at $176.75 (market cap $1.82B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 4.1× Boston Beer Company Inc's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Boston Beer Company Inc for 60 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SAM | SYRE | |
|---|---|---|
Market Cap | $1.82B | $7.52B |
Volume | 202,975 | 1,441,031 |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $108.92 |
52-Week Low | $161.08 | $22.18 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | $1.59B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAM trades at $178.14, up 1.74% today, near resistance at $178. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, 2025 revenue held at $1.96B with net income improving to $108M, yet 2026 guidance projects a net loss. The company is expanding its brand portfolio with new products and marketing initiatives to counter volume declines.
Outlook: SAM faces near-term headwinds from projected 2026 losses and competitive pressure, but brand investments and innovation provide growth avenues. Risks include execution challenges and weak consumer demand. The consensus price target of $204.44 implies potential upside, supported by a debt-free balance sheet, but investor sentiment remains cautious amid earnings misses.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
